Get the Stockscreener App
14.74
2.57%
-0.4563
Ars Pharmaceuticals Inc stock is traded at $14.74, with a volume of 260.71K.
It is down -2.57% in the last 24 hours and up +4.37% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$15.20
Open:
$15.4
24h Volume:
260.71K
Relative Volume:
0.23
Market Cap:
$1.45B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-30.35
EPS:
-0.4858
Net Cash Flow:
$-44.23M
1W Performance:
-2.37%
1M Performance:
+4.37%
6M Performance:
+51.90%
1Y Performance:
+292.84%
1-Day Range:
$14.67
$15.61
1-Week Range:
$14.10
$16.26
52-Week Range:
$3.38
$17.08
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Raymond James & Associates Buys New Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Consensus Target Price from Brokerages - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of “Buy” by Analysts - Defense World
Here's Why 'Trend' Investors Would Love Betting on ARS Pharmaceuticals, Inc. (SPRY) - MSN
Allspring Global Investments Holdings LLC Invests $2.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals shares a new treatment for allergic reactions - KATV
New Data on Needle Free Epinephrine Spray Presented at ACAAI 2024 - Patient Care Online
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data - GlobeNewswire
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5%Here's Why - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 12-Month HighHere's Why - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 4.3% HigherTime to Buy? - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY) is on the Move, Here's Why the Trend Could be Sustainable - MSN
ARS Pharmaceuticals' chief medical officer sells $1.49 million in stock By Investing.com - Investing.com Australia
Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation - Yahoo Finance
Ars Pharmaceuticals CFO Kathleen Scott sells $200,000 in stock - Investing.com
Ars Pharmaceuticals CFO Kathleen Scott sells $200,000 in stock By Investing.com - Investing.com Canada
Ars Pharmaceuticals CEO sells $1.49 million in stock By Investing.com - Investing.com South Africa
Ars Pharmaceuticals CEO sells $1.49 million in stock - Investing.com India
Kathleen D. Scott Sells 12,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock - MarketBeat
Innovating allergy drug delivery with a needle-free alternative - European Pharmaceutical Review
ARS Pharmaceuticals secures supply deal for neffy® microvials - Investing.com India
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 1-Year HighStill a Buy? - MarketBeat
Forget EpiPens. This San Diego biotech is offering the same medicine without needles - Chattanooga Times Free Press
Adversity is less terrifying than hope: ARS Pharmaceuticals Inc (SPRY) - SETE News
ARS Pharmaceuticals secures supply deal for neffy® microvials By Investing.com - Investing.com Canada
(SPRY) Technical Data - Stock Traders Daily
ARS Pharmaceuticals Inc’s results are impressive - US Post News
ARS Pharmaceuticals, Inc. is on the Move, Here's Why the Trend Could be Sustainable - Benzinga
Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade - Yahoo Finance
SG Americas Securities LLC Sells 53,288 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals executive sells over $1.38 million in company stock By Investing.com - Investing.com Australia
Ars Pharmaceuticals CEO sells over $1.38 million in company stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals executive sells over $1.38 million in company stock - Investing.com India
Ars Pharmaceuticals CEO sells over $1.38 million in company stock - Investing.com India
Richard E. Lowenthal Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock - MarketBeat
Podcast: Noticing Neffy – A ‘Transformative Treatment’ For Type 1 Allergies - medtech.citeline.com
ARS Pharmaceuticals Inc (SPRY)’s stock chart: A technical perspective - US Post News
Potential Price Increase for ARS Pharmaceuticals Inc (SPRY) After Recent Insider Activity - Knox Daily
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $24.00 - MarketBeat
Where ARS Pharmaceuticals Stands With Analysts - Benzinga
ARS Pharmaceuticals (NASDAQ:SPRY) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Upward Trajectory: ARS Pharmaceuticals Inc (SPRY) Posts a Gaine, Closing at 14.19 - The Dwinnex
Renaissance Technologies LLC Boosts Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) On The My Stocks Page - Stock Traders Daily
ARS Pharma’s Neffy poised to disrupt epinephrine market | Pharmaceutical | The Pharmaletter - The Pharma Letter
Neffy Nasal Spray: A New Era for Epinephrine Delivery by ARS Pharmaceuticals Copy - Zenopa
Neffy Nasal Spray: A New Era for Epinephrine Delivery by ARS Pharmaceuticals - Zenopa
Renaissance supports nasal spray launch for life-threatening allergies - European Pharmaceutical Manufacturer
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):